NBIX insider trading
HealthcareNEUROCRINE BIOSCIENCES INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About NEUROCRINE BIOSCIENCES INC
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Company website: www.neurocrine.com
NBIX insider activity at a glance
FilingIQ has scored 1,324 insider transactions for NBIX since Jan 8, 2015. The most recent filing in our index is dated May 12, 2026.
Across the full history, 0 open-market purchases
and 708 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on NBIX insider trades is 62.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest NBIX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding NBIX
Frequently asked
- How many insider trades does FilingIQ track for NBIX?
- FilingIQ tracks 1,324 Form 4 insider transactions for NBIX (NEUROCRINE BIOSCIENCES INC), covering filings from Jan 8, 2015 onwards. 3 of those were filed in the last 90 days.
- Are NBIX insiders net buyers or net sellers?
- Across the full Form 4 history for NBIX, 0 transactions (0%) were open-market purchases and 708 (53%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does NBIX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is NBIX in?
- NEUROCRINE BIOSCIENCES INC (NBIX) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $12.82B.
Methodology & sources
Every NBIX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.